Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $264,000.00 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the transaction, the senior vice president now directly owns 336,918 shares in the company, valued at approximately $3,706,098. This represents a 6.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rhonda Farnum also recently made the following trade(s):

• On Monday, April 21st, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Stock Performance

Shares of TBPH stock traded up $0.48 during trading hours on Friday, reaching $11.25. The company had a trading volume of 295,003 shares, compared to its average volume of 263,240. The company has a market capitalization of $562.51 million, a P/E ratio of -11.14 and a beta of -0.10. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $11.82. The stock's fifty day simple moving average is $9.31 and its 200 day simple moving average is $9.39.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, equities analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Institutional Investors Weigh In On Theravance Biopharma

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in Theravance Biopharma by 3.5% in the 4th quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock worth $433,000 after buying an additional 1,576 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Theravance Biopharma by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock worth $1,049,000 after acquiring an additional 1,720 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after acquiring an additional 2,060 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock worth $556,000 after acquiring an additional 2,293 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at about $25,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $11.33.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.